Cabaletta Bio (CABA) Profit After Tax (2018 - 2026)
Cabaletta Bio (CABA) posted quarterly Profit After Tax of -$41.9 million for Q4 2025, down 28.63% year-over-year from -$58.7 million in Q4 2024, and up 6.57% quarter-over-quarter from -$44.9 million in Q3 2025.
Analysis
Cabaletta Bio (CABA) Profit After Tax (2018 - 2026) Analysis & Trends
Cabaletta Bio's Profit After Tax history runs 8 years deep, the most recent figure standing at -$41.9 million for Q4 2025.
- In Q4 2025, Profit After Tax fell 28.63% year-over-year to -$41.9 million; the TTM figure through Dec 2025 stood at -$167.9 million (down 44.91% YoY), while the FY2025 annual figure was -$167.8 million, down 44.8% from the prior year.
- Profit After Tax for Q4 2025 stood at -$41.9 million, up from -$44.9 million in the prior quarter.
- The five-year high for Profit After Tax was -$9.7 million in Q1 2021, with the low at -$45.1 million in Q2 2025.
- The 5-year median for Profit After Tax is -$16.2 million (2023), against an average of -$22.5 million.
- The sharpest annual moves came in 2022 and 2024: Profit After Tax increased 1.16% in 2022, then slumped 90.53% in 2024.
- Cabaletta Bio's Profit After Tax stood at -$13.9 million in 2021, then declined by 13.38% to -$15.7 million in 2022, then slumped by 32.02% to -$20.8 million in 2023, then sank by 56.83% to -$32.6 million in 2024, then dropped by 28.63% to -$41.9 million in 2025.
- Business Quant data shows CABA's Profit After Tax at -$41.9 million in Q4 2025, -$44.9 million in Q3 2025, and -$45.1 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Cabaletta Bio | 522.26 Mn | 522.26 Mn | - | -51.02 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -51.02 Mn |
| Dec 31, 2025 | -41.92 Mn |
| Sep 30, 2025 | -44.87 Mn |
| Jun 30, 2025 | -45.13 Mn |
| Mar 31, 2025 | -35.94 Mn |
| Dec 31, 2024 | -32.59 Mn |
| Sep 30, 2024 | -30.63 Mn |
| Jun 30, 2024 | -27.60 Mn |
| Mar 31, 2024 | -25.05 Mn |
| Dec 31, 2023 | -20.87 Mn |
| Sep 30, 2023 | -16.47 Mn |
| Jun 30, 2023 | -14.49 Mn |
| Mar 31, 2023 | -15.85 Mn |
| Dec 31, 2022 | -15.53 Mn |
| Sep 30, 2022 | -11.43 Mn |
| Jun 30, 2022 | -12.91 Mn |
| Mar 31, 2022 | -12.95 Mn |
| Dec 31, 2021 | -13.88 Mn |
| Sep 30, 2021 | -11.56 Mn |
| Jun 30, 2021 | -11.14 Mn |